{'fraction_non_alphanumeric': 0.022435897435897436, 'fraction_numerical': 0.007051282051282051, 'mean_word_length': 6.363207547169812, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

When advanced prostate cancer recurred during hormonal therapy and became the castration‐resistant prostate cancer, “vintage hormonal therapy,” such as antiandrogen alternating therapy or estrogen‐related hormonal therapy, was widely carried out in Japan until 2013. This vintage hormonal therapy controlled the progression of castration‐resistant prostate cancer. When castration‐resistant prostate cancer relapses during these therapies, chemotherapy using docetaxel has been carried out subsequently. Since new hormonal therapies using abiraterone acetate and enzalutamide, which improve the prognosis of castration‐resistant prostate cancer, became available in Japan from 2014, therapeutic options for castration‐resistant prostate cancer have increased. Furthermore, the improvement of the further prognosis is promising by using cabazitaxel for docetaxel‐resistant castration‐resistant prostate cancer and radium‐223 for castration‐resistant prostate cancer with bone metastasis. An increase in therapeutic options gives rise to many questions, including best timing to use them and the indication. Furthermore, physicians have to consider the treatment for the recurrence after having carried out chemotherapy. We want to argue the difference in hormonal therapy between Japan and Western countries, and problems when carrying out new treatments, and the importance of imaging in the present review article.